India's drug regulatory authority is urging all states to implement consistent licensing guidelines for drug manufacturing. This initiative aims to ensure that quality standards are uniformly maintained across the country.
The Drugs Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, issued a directive in February, emphasizing the need for a comprehensive guidance document that mandates a dossier-based licensing system. This approach seeks to eliminate regional discrepancies in regulatory practices and enforce a single, rigorous standard for drug approvals nationwide.
State licensing authorities are now required to adopt this guidance and report back to the DCGI on their progress. By enforcing good manufacturing practices, the DCGI aims to elevate the standards for all companies operating within India's significant pharmaceutical sector.
Historically, drug licensing in India has suffered from a lack of uniformity, with state authorities imposing varying requirements. This inconsistency has raised concerns about the overall quality of drugs produced in India, often referred to as the "pharmacy of the world" due to its capacity to manufacture affordable generic medications.
The new dossier-based approach shifts the focus from individual evaluations to a structured assessment of comprehensive data submitted by manufacturers. This change necessitates that manufacturers provide detailed information through the Online National Drugs Licensing System portal, addressing quality, safety, and efficacy concerns.
The guidance document features a detailed 41-item checklist divided into two sections. Part A covers administrative and facility-related information, while Part B focuses on technical data regarding the drug, including stability and validation data. Notably, the technical submission is made through Form 29, which allows manufacturers to produce small batches for testing under regulated conditions.
Despite these advancements, some industry experts express concern that smaller companies may struggle to comply due to the high costs associated with necessary testing equipment. Dr. G.L. Singhal, a former drug controller, noted that while larger firms might easily adapt, smaller entities could face challenges in moving beyond mere compliance to genuinely improving drug quality.
As the DCGI continues to implement these changes, the focus remains on closing regulatory gaps and ensuring that all manufacturers adhere to the same high standards.
